Analysts Upgrades

Esperion Therapeutics Inc. (ESPR) Rating Increased to Strong-Buy at Vetr Inc.

Esperion Therapeutics Inc. (ESPR) Rating Increased to Strong-Buy at Vetr Inc.

Esperion Therapeutics Inc. (NASDAQ:ESPR) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Monday. The firm presently has a $12.60 target price on the biopharmaceutical company’s stock. Vetr‘s target price suggests a potential upside of 18.09% from the company’s previous close. Esperion Therapeutics […]
Darling Ingredients Inc. (DAR) Rating Increased to Hold at Zacks Investment Research

Darling Ingredients Inc. (DAR) Rating Increased to Hold at Zacks Investment Research

Darling Ingredients Inc. (NYSE:DAR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday. According to Zacks, “Darling Ingredients Inc. is a provider of rendering, cooking oil and bakery waste recycling and recovery solutions. It collects and transforms all aspects of animal by-product […]
Kinross Gold Corp. (KGC) Upgraded to “Buy” by Vetr Inc.

Kinross Gold Corp. (KGC) Upgraded to “Buy” by Vetr Inc.

Kinross Gold Corp. (NYSE:KGC) was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating in a research note issued on Monday. The brokerage presently has a $5.63 price target on the mining company’s stock. Vetr‘s price objective indicates a potential upside of 28.83% from the company’s previous close. KGC has been […]
Johnson & Johnson (JNJ) Upgraded to Hold at Vetr Inc.

Johnson & Johnson (JNJ) Upgraded to Hold at Vetr Inc.

Johnson & Johnson (NYSE:JNJ) was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating in a report issued on Monday. The brokerage currently has a $124.21 price target on the stock. Vetr‘s price target points to a potential upside of 3.58% from the company’s current price. In other Johnson & Johnson […]
Clarcor Inc. (CLC) Rating Increased to Hold at Zacks Investment Research

Clarcor Inc. (CLC) Rating Increased to Hold at Zacks Investment Research

Clarcor Inc. (NYSE:CLC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday. According to Zacks, “Clarcor Inc. is a diversified marketer and manufacturer of mobile, industrial and environmental filtration products and consumer and industrial packaging products sold in domestic […]
Cidara Therapeutics Inc. (CDTX) Stock Rating Upgraded by Zacks Investment Research

Cidara Therapeutics Inc. (CDTX) Stock Rating Upgraded by Zacks Investment Research

Cidara Therapeutics Inc. (NASDAQ:CDTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 […]
Coca-Cola Amatil Ltd. (CCLAY) Rating Increased to Buy at Zacks Investment Research

Coca-Cola Amatil Ltd. (CCLAY) Rating Increased to Buy at Zacks Investment Research

Coca-Cola Amatil Ltd. (OTCMKTS:CCLAY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The brokerage currently has a $8.25 price objective on the stock. Zacks Investment Research’s target price would indicate a potential upside of 12.32% from the company’s previous close. According to […]
Barrick Gold Corp. (ABX) Upgraded at Vetr Inc.

Barrick Gold Corp. (ABX) Upgraded at Vetr Inc.

Barrick Gold Corp. (NYSE:ABX) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday. The brokerage currently has a $24.34 target price on the stock. Vetr‘s target price suggests a potential upside of 32.35% from the stock’s current price. Other equities analysts […]
Vetr Inc. Upgrades CenturyLink Inc. (CTL) to Hold

Vetr Inc. Upgrades CenturyLink Inc. (CTL) to Hold

CenturyLink Inc. (NYSE:CTL) was upgraded by research analysts at Vetr from a “sell” rating to a “hold” rating in a research note issued on Monday. The brokerage presently has a $29.00 target price on the stock. Vetr‘s price objective suggests a potential upside of 0.87% from the stock’s previous close. In other CenturyLink news, Director […]
Accelerate Diagnostics Inc. (AXDX) Upgraded to Hold by Zacks Investment Research

Accelerate Diagnostics Inc. (AXDX) Upgraded to Hold by Zacks Investment Research

Accelerate Diagnostics Inc. (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday. According to Zacks, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a […]
Axa SA (AXAHY) Raised to Hold at Zacks Investment Research

Axa SA (AXAHY) Raised to Hold at Zacks Investment Research

Axa SA (NASDAQ:AXAHY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday. According to Zacks, “The AXA Group is an international group of insurance and related financial services companies. AXA’s insurance operations are diverse geographically, with activities in 50 countries, principally Western […]
Liberty Braves Group (BATRK) Lifted to Buy at Zacks Investment Research

Liberty Braves Group (BATRK) Lifted to Buy at Zacks Investment Research

Liberty Braves Group (NASDAQ:BATRK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $19.00 price objective on the stock. Zacks Investment Research’s target price indicates a potential upside of 14.67% from the company’s previous […]
Abeona Therapeutics Inc. (ABEO) Rating Increased to Hold at Zacks Investment Research

Abeona Therapeutics Inc. (ABEO) Rating Increased to Hold at Zacks Investment Research

Abeona Therapeutics Inc. (NASDAQ:ABEO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday. According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., […]
Bellicum Pharmacueticals Inc. (BLCM) Upgraded to Hold at Zacks Investment Research

Bellicum Pharmacueticals Inc. (BLCM) Upgraded to Hold at Zacks Investment Research

Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday. According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological […]
Infoblox Inc. (BLOX) Upgraded to Buy at Zacks Investment Research

Infoblox Inc. (BLOX) Upgraded to Buy at Zacks Investment Research

Infoblox Inc. (NYSE:BLOX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The firm currently has a $23.00 price target on the stock. Zacks Investment Research’s price objective would indicate a potential upside of 13.75% from the company’s previous close. According to Zacks, “Infoblox […]
Content on this website is not meant to be a recommendation or an offer to buy or sell any security. Click here to read our full disclaimer.